CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70—A Retrospective Study

SIMPLE SUMMARY: To assess prognosis in myelofibrosis (MF), age and degree of anemia and leukocytosis are taken into account together with the presence of blasts in the peripheral blood and constitutional symptoms (fever, night sweats, weight loss). The latter are signs of systemic inflammation, which plays a pivotal role in MF pathophysiology. Considering information about genetic changes can refine prognostication. The goal of our retrospective study was to assess the prognostic impact of two laboratory markers of inflammation that are readily available in clinical routine at low costs: C-reactive protein (CRP) and albumin. We found a significant prognostic impact of both parameters either alone or combined within the CRP/albumin ratio or the Glasgow Prognostic Score, which was independent of the Mutation-Enhanced International Prognostic Scoring System (MIPSS)-70. Therefore, assessing CRP and albumin helps to identify a vulnerable population of MF patients, which eludes current prognostic models, even if the presence of high-risk mutations is considered. ABSTRACT: In myelofibrosis, the C-reactive protein (CRP)/albumin ratio (CAR) and the Glasgow Prognostic Score (GPS) add prognostic information independently of the Dynamic International Prognostic Scoring System (DIPSS). Their prognostic impact, if molecular aberrations are considered, is currently unknown. We performed a retrospective chart review of 108 MF patients (prefibrotic MF n = 30; primary MF n = 56; secondary MF n = 22; median follow-up 42 months). In MF, both a CAR > 0.347 and a GPS > 0 were associated with a shorter median overall survival (21 [95% CI 0–62] vs. 80 months [95% CI 57–103], p < 0.001 and 32 [95% CI 1–63] vs. 89 months [95% CI 65–113], p < 0.001). Both parameters retained their prognostic value after inclusion into a bivariate Cox regression model together with the dichotomized Mutation-Enhanced International Prognostic Scoring System (MIPSS)-70: CAR > 0.374 HR 3.53 [95% CI 1.36–9.17], p = 0.0095 and GPS > 0 HR 4.63 [95% CI 1.76–12.1], p = 0.0019. An analysis of serum samples from an independent cohort revealed a correlation of CRP with levels of interleukin-1β and albumin with TNF-α, and demonstrated that CRP was correlated to the variant allele frequency of the driver mutation, but not albumin. Albumin and CRP as parameters readily available in clinical routine at low costs deserve further evaluation as prognostic markers in MF, ideally by analyzing data from prospective and multi-institutional registries. Since both albumin and CRP levels reflect different aspects of MF-associated inflammation and metabolic changes, our study further highlights that combining both parameters seems potentially useful to improve prognostication in MF.